



Bristol-Myers Squibb

US Pharmaceuticals
P.O. Box 4500
Princeton, NJ 08543-4500
609-897-2000

May 4, 2006

Dear Customer,

We are sending this to letter to inform you that Bristol-Myers Squibb has decided to discontinue the commercialization of TEQUIN[®] (gatifloxacin) Tablets and Injection in the countries where Bristol-Myers Squibb markets the product.

Following consideration of the commercial potential of this antibiotic both globally and within our United States product portfolio as well as the ongoing transition of the Bristol-Myers Squibb pharmaceutical strategy to a specialty-driven focus, we have decided to cease shipping the product to wholesalers in the United States effective June 2, 2006.

You may thereafter elect to retain your current inventory of the product to fill any open orders or return the product to us under our standard returns policy. A list of the units to be discontinued is provided in Attachment A.

If you have any questions related to this announcement, please don't hesitate to call your Bristol-Myers Squibb Account Director or me at 609.897.2412.

Thank you for your continued support of Bristol-Myers Squibb products.

Sincerely yours,

Vincent J. Bilinsky
Vice-President, Trade Sales/Operations

Attachment A

Discontinued Products

Product	List Number	NDC Number	Description
TEQUIN	118078	0015-1180-78	SINJ 2MG/ML (1BAGX100ML)BAXTER US
TEQUIN	118079	0015-1180-79	SINJ 2MG/ML (1BAGX100ML) – old NDC
TEQUIN	118178	0015-1181-78	SINJ 2MG/ML (1BAGX200ML)BAXTER US
TEQUIN	118179	0015-1181-79	SINJ 2MG/ML (1BAGX200ML) – old NDC
TEQUIN	117980	0015-1179-80	SINJ 10MG/ML (1VLX40ML) US
TEQUIN	111780	0015-1117-80	TAB 200MG (10BLPX10) HUD US
TEQUIN	117780	0015-1177-80	TAB 400MG (10BLPX10) HUD US
TEQUIN	111750	0015-1117-50	TAB 200MG (1BTLX30) US
TEQUIN	117760	0015-1177-60	TAB 400MG (1BTLX50) US
TEQUIN	117721	0015-1177-21	TAB 400MG (3BLPX5) US